434 related articles for article (PubMed ID: 32338295)
1. Impact of circulating tumor DNA in hepatocellular and pancreatic carcinomas.
Dhayat SA; Yang Z
J Cancer Res Clin Oncol; 2020 Jul; 146(7):1625-1645. PubMed ID: 32338295
[TBL] [Abstract][Full Text] [Related]
2. Circulating tumor DNA as an emerging liquid biopsy biomarker for early diagnosis and therapeutic monitoring in hepatocellular carcinoma.
Wu X; Li J; Gassa A; Buchner D; Alakus H; Dong Q; Ren N; Liu M; Odenthal M; Stippel D; Bruns C; Zhao Y; Wahba R
Int J Biol Sci; 2020; 16(9):1551-1562. PubMed ID: 32226301
[TBL] [Abstract][Full Text] [Related]
3. Combining tissue and circulating tumor DNA increases the detection rate of a CTNNB1 mutation in hepatocellular carcinoma.
Oversoe SK; Clement MS; Weber B; Grønbæk H; Hamilton-Dutoit SJ; Sorensen BS; Kelsen J
BMC Cancer; 2021 Apr; 21(1):376. PubMed ID: 33827453
[TBL] [Abstract][Full Text] [Related]
4. Genomic Landscape of Liquid Biopsy for Hepatocellular Carcinoma Personalized Medicine.
Moldogazieva NT; Zavadskiy SP; Terentiev AA
Cancer Genomics Proteomics; 2021; 18(3 Suppl):369-383. PubMed ID: 33994362
[TBL] [Abstract][Full Text] [Related]
5. Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer.
Patel H; Okamura R; Fanta P; Patel C; Lanman RB; Raymond VM; Kato S; Kurzrock R
J Hematol Oncol; 2019 Dec; 12(1):130. PubMed ID: 31801585
[TBL] [Abstract][Full Text] [Related]
6. Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma.
Xu RH; Wei W; Krawczyk M; Wang W; Luo H; Flagg K; Yi S; Shi W; Quan Q; Li K; Zheng L; Zhang H; Caughey BA; Zhao Q; Hou J; Zhang R; Xu Y; Cai H; Li G; Hou R; Zhong Z; Lin D; Fu X; Zhu J; Duan Y; Yu M; Ying B; Zhang W; Wang J; Zhang E; Zhang C; Li O; Guo R; Carter H; Zhu JK; Hao X; Zhang K
Nat Mater; 2017 Nov; 16(11):1155-1161. PubMed ID: 29035356
[TBL] [Abstract][Full Text] [Related]
7. Analysis of Tissue and Circulating Tumor DNA by Next-Generation Sequencing of Hepatocellular Carcinoma: Implications for Targeted Therapeutics.
Ikeda S; Lim JS; Kurzrock R
Mol Cancer Ther; 2018 May; 17(5):1114-1122. PubMed ID: 29483209
[TBL] [Abstract][Full Text] [Related]
8. Liquid biopsy in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA.
Ye Q; Ling S; Zheng S; Xu X
Mol Cancer; 2019 Jul; 18(1):114. PubMed ID: 31269959
[TBL] [Abstract][Full Text] [Related]
9. Prospects and challenges of circulating tumor DNA in precision medicine of hepatocellular carcinoma.
Weng J; Atyah M; Zhou C; Ren N
Clin Exp Med; 2020 Aug; 20(3):329-337. PubMed ID: 32239299
[TBL] [Abstract][Full Text] [Related]
10. Identification of mutations in circulating cell-free tumour DNA as a biomarker in hepatocellular carcinoma.
Howell J; Atkinson SR; Pinato DJ; Knapp S; Ward C; Minisini R; Burlone ME; Leutner M; Pirisi M; Büttner R; Khan SA; Thursz M; Odenthal M; Sharma R
Eur J Cancer; 2019 Jul; 116():56-66. PubMed ID: 31173963
[TBL] [Abstract][Full Text] [Related]
11. Circulating tumor DNA profiling reveals clonal evolution and real-time disease progression in advanced hepatocellular carcinoma.
Cai ZX; Chen G; Zeng YY; Dong XQ; Lin MJ; Huang XH; Zhang D; Liu XL; Liu JF
Int J Cancer; 2017 Sep; 141(5):977-985. PubMed ID: 28543104
[TBL] [Abstract][Full Text] [Related]
12. Personalized circulating tumor DNA in patients with hepatocellular carcinoma: a pilot study.
Pommergaard HC; Yde CW; Ahlborn LB; Andersen CL; Henriksen TV; Hasselby JP; Rostved AA; Sørensen CL; Rohrberg KS; Nielsen FC; Rasmussen A
Mol Biol Rep; 2022 Feb; 49(2):1609-1616. PubMed ID: 34811635
[TBL] [Abstract][Full Text] [Related]
13. Detection of MET gene somatic mutations in hepatocellular carcinoma of Egyptian patients using next-generation sequencing.
Ahmed E; El-Dien A N; Sabet S; Khalifa M; El Hamshary M
Biomarkers; 2023 Jun; 28(4):379-386. PubMed ID: 36825430
[TBL] [Abstract][Full Text] [Related]
14. Current status of ctDNA in precision oncology for hepatocellular carcinoma.
Li Y; Zheng Y; Wu L; Li J; Ji J; Yu Q; Dai W; Feng J; Wu J; Guo C
J Exp Clin Cancer Res; 2021 Apr; 40(1):140. PubMed ID: 33902698
[TBL] [Abstract][Full Text] [Related]
15. Prediction of the prognosis of advanced hepatocellular carcinoma by TERT promoter mutations in circulating tumor DNA.
Hirai M; Kinugasa H; Nouso K; Yamamoto S; Terasawa H; Onishi Y; Oyama A; Adachi T; Wada N; Sakata M; Yasunaka T; Onishi H; Shiraha H; Takaki A; Okada H
J Gastroenterol Hepatol; 2021 Apr; 36(4):1118-1125. PubMed ID: 32830343
[TBL] [Abstract][Full Text] [Related]
16. Circulating-Free DNA Analysis in Hepatocellular Carcinoma: A Promising Strategy to Improve Patients' Management and Therapy Outcomes.
Mezzalira S; De Mattia E; Guardascione M; Dalle Fratte C; Cecchin E; Toffoli G
Int J Mol Sci; 2019 Nov; 20(21):. PubMed ID: 31694149
[TBL] [Abstract][Full Text] [Related]
17. The use of minimally invasive biomarkers for the diagnosis and prognosis of hepatocellular carcinoma.
Trevisan França de Lima L; Broszczak D; Zhang X; Bridle K; Crawford D; Punyadeera C
Biochim Biophys Acta Rev Cancer; 2020 Dec; 1874(2):188451. PubMed ID: 33065194
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive Liquid Profiling of Circulating Tumor DNA and Protein Biomarkers in Long-Term Follow-Up Patients with Hepatocellular Carcinoma.
Cai Z; Chen G; Zeng Y; Dong X; Li Z; Huang Y; Xin F; Qiu L; Xu H; Zhang W; Su X; Liu X; Liu J
Clin Cancer Res; 2019 Sep; 25(17):5284-5294. PubMed ID: 31217202
[TBL] [Abstract][Full Text] [Related]
19. [The role of circulating tumor DNA in the diagnosis and prognosis of hepatocellular carcinoma].
Fan ZH; Ren F
Zhonghua Gan Zang Bing Za Zhi; 2022 Dec; 30(12):1382-1386. PubMed ID: 36891725
[TBL] [Abstract][Full Text] [Related]
20. The Use of ctDNA in the Diagnosis and Monitoring of Hepatocellular Carcinoma-Literature Review.
Kopystecka A; Patryn R; Leśniewska M; Budzyńska J; Kozioł I
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
